UroGen Pharma Ltd. 10-Q

Item 5. Other Information.   None.   80 Table of Contents   Item 6. Exhibits.   The following exhibits are filed as part of this report:   Exhibit Number   Description       3.1   Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant ’ s Form 6-K (File No. 001-38079), filed with the SEC on May 18, 2017).       4.1   Form of July 2023   Pre-Funded   Warrant (incorporated by reference to Exhibit 4.1 to the Registrant ’ s Current Report on Form 8-K (File No. 001-38079), filed with the SEC on July 27, 2023).       10.1*   2017 Equity Incentive Plan, as amended.       10.2   Securities Purchase Agreement, dated July 26, 2023, by and among UroGen Pharma Ltd. and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38079), filed with the SEC on July 27, 2023).       10.3   Form of Stock Option Grant Notice and Stock Option Agreement under the Urogen Pharma Ltd. 2017 Equity Incentive Plan.       10.4   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Urogen Pharma Ltd. 2017 Equity Incentive Plan.       10.5   Form of Performance-Based Restricted Stock Unit Grant Notice and Performance-Based Restricted Stock Unit Award Agreement under the Urogen Pharma Ltd. 2017 Equity Incentive Plan.       10.6   Performance-Based Restricted Stock Unit Grant Notice by and between the Registrant and Elizabeth Barrett, dated as of November 13, 2023.       31.1   Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       31.2   Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       32.1#   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.       32.2#   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.       101.INS   Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document       101.SCH   Inline XBRL Taxonomy Extension Schema Document       101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document       101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document       101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document       101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document       104   The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL   * Management contract or compensatory plan. # The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.   81 Table of Contents   Signatures   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.       UroGen Pharma Ltd.         November 14, 2023   By: /s/ Elizabeth Barrett       Elizabeth Barrett       Chief Executive Officer (Principal Executive Officer)         November 14, 2023   By: /s/ Don Kim       Don Kim       Chief Financial Officer (Principal Financial and Accounting Officer)   82